About Bioqube Ventures
Bioqube Ventures is a venture capital firm founded in 2016. It is primarily based out of Brussels, Belgium. As of Jan 2026, Bioqube Ventures has invested in 10 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across Life Sciences and Healthcare sectors. Most recently it participated in the $***** Series B round of Primmune Therapeutics Overall, Bioqube Ventures portfolio has seen 1 IPO, namely Bicara Therapeutics. A lot of funds co-invest with Bioqube Ventures, with names like Omega Funds sharing a substantial percentage of its portfolio. Bioqube Ventures has team of 13 people including 7 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 2 more
Portfolio IPOs
Deals in last 12 months
Bioqube Ventures' List of Top Investments
Bioqube Ventures has a portfolio of 10 companies. Their most notable investments are in Primmune Therapeutics and CatalYm.Their portfolio spans across United States, France, Denmark and 3 more locations. They have invested in Life Sciences, Healthcare, across Series A, Seed and 2 more. Here is the list of top investments by Bioqube Ventures:
Developer of therapies for cancer treatment. The company's product line include BCA101, BCA300, BCA202, and BCA400 are tumor-targeting antibodies. These bifunctional molecules only target the tumor and not damage or destroy the healthy cells and minimize the side effects.
Key facts about Bicara Therapeutics
- Founded Year: 2019
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $313M
- Employee Count: 144 as on Sep 30, 2026
- Investors: RA Capital Management, Janus Henderson Investors and 16 Others
- Latest Funding Round: Series C, Dec 12, 2023, $*****
- Highlight: Public
Primmune Therapeutics is developing immunotherapies for treating cancer. They are developing a small molecule (orally administered) which is a toll-like receptor 7 (TLR7) agonist (an endosomal innate immune sensor capable of detecting single-stranded ribonucleic acid) helps in systemic activation of innate immunity. It gets expressed on plasmacytoid dendritic cells.
Key facts about Primmune Therapeutics
- Founded Year: 2017
- Location: San Diego (United States)
- Stage: Series B
- Total Funding till date: $60M
- Employee Count: 9 as on Aug 31, 2026
- Investors: Oberland Capital, CAM Capital and 8 Others
- Latest Funding Round: Series B, Jan 26, 2026, $*****
- Highlight: Editors' Pick
3. CatalYm
Developer of drugs for the treatment of cancer. The lead candidate includes CTL-002 which works by neutralizing tumour-produced proteins called GDF-15. It is used to treat cancer and autoimmune disease.
Key facts about CatalYm
- Founded Year: 2016
- Location: Munich (Germany)
- Stage: Series D
- Total Funding till date: $261M
- Employee Count: 56 as on Sep 30, 2026
- Investors: Gilde Healthcare, Canaan and 20 Others
- Latest Funding Round: Series D, Jul 16, 2024, $*****
- Highlight: Editors' Pick
4. Actithera
Actithera is a radiopharmaceutical company developing novel radiotherapeutics for cancer treatment. Leveraging a unique medicinal chemistry approach, the company aims to discover and develop theranostics with prolonged tumor retention. With a strong focus on precision medicine, Actithera is poised to revolutionize the treatment of cancer through targeted radiotherapy.
Key facts about Actithera
- Founded Year: 2021
- Location: Cambridge (United States)
- Stage: Series A
- Total Funding till date: $80.8M
- Employee Count: 35 as on Aug 31, 2026
- Investors: 4Bio Capital, Surveyor Capital and 7 Others
- Latest Funding Round: Series A, Jul 09, 2025, $*****
- Highlight: Editors' Pick
Provider of T cells-based therapeutics for oncology and autoimmune disease. The company offers computational-based IL-2 modified variants and translational-based therapeutic Treg targets to restore the immune response.
Key facts about Egle Therapeutics
- Founded Year: 2020
- Location: Paris (France)
- Stage: Series A
- Total Funding till date: $46.6M
- Employee Count: 52 as on Aug 31, 2026
- Investors: Life Sciences Partners, EQT and 5 Others
- Latest Funding Round: Grant (prize money), Mar 17, 2025, $*****
- Highlight: Editors' Pick
Bioqube Ventures' Year-on-Year Investment Trends
Bioqube Ventures has invested in 10 companies over the last 5 years, with an average of 2 new investments annually in the last 5 years. In 2025, it made 1 investment, while as of Jan 2026, it has made 1 investment in this year. Its most recent first time investment was in Actithera and most recent follow-on round was in Primmune Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 1 | 0 | 1 |
2024 | 3 | 0 | 3 |
2023 | 1 | 1 | 2 |
2022 | 2 | 0 | 2 |
2021 | 3 | 0 | 3 |
Bioqube Ventures' Investments by Stage
Bioqube Ventures has made 5 investments in Series A stage with an average round size of $30.7M, 2 investments in Seed stage with an average round size of $20.6M, 2 investments in Series B stage with an average round size of $91.5M and 1 investment in Series D stage with an average round size of $150M.Stage of entry | No. of Investments |
|---|---|
Series A | 5 |
Seed | 2 |
Series B | 2 |
Series D | 1 |
Note: We have considered here, only first round of investments
Bioqube Ventures' Investments by Sector
Bioqube Ventures has a diverse portfolio, with companies operating in the Life Sciences and Healthcare. Notably, it has invested in 8 Tech companies, 7 Enterprise (B2B) companies, 1 Social impact company and 1 company focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 8 |
Healthcare | 1 |
Note: We have considered here, only first round of investments
Bioqube Ventures' Investments by Geography
Bioqube Ventures has made most investments in United States (3), followed by France where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 3 |
France | 2 |
United Kingdom | 2 |
Denmark | 1 |
Germany | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Bioqube Ventures' recent investments
Bioqube Ventures has made 1 investments in 2026 so far - Primmune Therapeutics.Here are the most recent investments by Bioqube Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 26, 2026 | United States | Series B | 7368 | [+1] | |
Jul 09, 2025 | United States | Series A | 6534 | [+7] | |
Jul 16, 2024 | Germany | Series D | 3770 | [+7] | |
May 09, 2024 | Denmark | Seed | 6474 | ||
Apr 22, 2024 | United Kingdom | Series B | 5118 | [+1] |
IPOs and Publicly Listed companies in Bioqube Ventures' Portfolio
1 of Bioqube Ventures' portfolio company became public - Bicara Therapeutics. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2024 at marketcap of $932MHere are Bioqube Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 13, 2024 | Mar 06, 2023 | Series B | 4586 |
Team profile of Bioqube Ventures
Bioqube Ventures has a team of 13 members including 7 Partners and 2 Principals located in Belgium, United States and 1 more location. Bioqube Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in Bioqube Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Belgium | - | ||
Partner | Belgium | - | - | |
Partner | Belgium | - | ||
Partner | Belgium | - | - | |
Partner | Newtown | - | - | |
Partner | Belgium | - | ||
Partner | Switzerland | - | - | |
Principal | Brussels | - | ||
Principal | Belgium | - | - |
Co-investors of Bioqube Ventures
Over the past 5 years, 63 investors have co-invested in Bioqube Ventures's portfolio companies. This includes funds and angels.
- Invested before Bioqube Ventures: Forbion, Biocon and 22 others have invested in rounds before Bioqube Ventures. There are 2 companies where Forbion has invested before Bioqube Ventures and 1 company where Biocon has invested before Bioqube Ventures.
- Top Co-investors of Bioqube Ventures: 31 investors entered a company along with Bioqube Ventures. These include investors like Omega Funds (2 companies).
- Invested after Bioqube Ventures: A total of 8 investors have invested in Bioqube Ventures's portfolio after their investments. Top Investors include Braidwell (1 company), TPG (1 company) and Deerfield (1 company).
Recent News related to Bioqube Ventures
•
Primmune Therapeutics Announces Additional Close of Series B FinancingBenzinga•Jan 26, 2026•Primmune Therapeutics, Samsara BioCapital, Oberland Capital, Bioqube Ventures
•
Commit Biologics Raises €5.5M in Seed Financing ExtensionFinSMEs•Jan 28, 2025•Commit Biologics, Korys, Novo Holdings, Bioqube Ventures
•
Dublin-based SynOx adds new capital to Series B, raising total to €84.8 millionEU-Startups•Oct 30, 2024•SynOx, Gilde Healthcare, Forbion, Healthcap and 1 other
•
CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series DPulse 2.0•Jul 27, 2024•CatalYm, Canaan, Bioqube Ventures, Forbion and 6 others
•
Catalym’s GDF15-targeting cancer drug draws $150M series DBioWorld•Jul 16, 2024•CatalYm, Canaan, Bioqube Ventures, Jeito and 6 others
•
Commit Biologics: €16 Million Raised To Build Systems For Treating Cancer And Autoimmune DiseasesPulse 2.0•May 17, 2024•Commit Biologics, Bioqube Ventures, Novo Holdings
•
Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune diseasePR Newswire•May 09, 2024•Commit Biologics, Bioqube Ventures, Novo Holdings
•
Commit Biologics advances complement platform with €16m seed financingBioPharma-Reporter•May 09, 2024•Commit Biologics, Bioqube Ventures, Novo Holdings
•
Novo Holdings-backed Commit launches with $17.2m in seed fundingPharmaceutical Technology•May 09, 2024•Commit Biologics, New Nordic, Bioqube Ventures
•
Biopharma firm SynOx Therapeutics raises $75m in funding roundIndependent.ie•Apr 22, 2024•SynOx, Forbion, Healthcap, Bioqube Ventures and 2 others
